Alzheimer’s disease

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KINSUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanema...

The advancement of technology has ushered in an era where the fusion of biology and electronics is becoming increasingly seamless. One of the most groundbreaking innovations in this domain is wireless brain sensors. These devices promise to revolutionize neuroscience research, enhance healthcare delivery, and impro...

The Tropion-Lung01 Phase III Trial Reveals that Datopotamab Deruxtecan Significantly Enhanced Overall Survival in Advanced Nonsquamous NSCLC Patients Compared to Chemotherapy The high-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which had previously met the dual primary endpoint o...

IMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following pl...

Takeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, int...

The healthcare market has witnessed a remarkable transformation in recent years, largely driven by rapid advancements in technology and innovation. Among the most notable developments is the evolution of wearable medical devices, which have transcended their traditional roles to become indispensable tools in the mo...

Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owne...

Alzheimer’s Disease represents one of the most pressing challenges in today's healthcare market. As its prevalence continues to soar with the aging global population, the hurdles in its diagnostic and treatment also continue to rise. As per the estimate, globally, about 55 million people are living with dementia in...

Alzheimer’s, the most common type of dementia, particularly with an increasing geriatric population, presents a major global crisis. The disease mostly occurs in sexagenarians, but it may manifest in quadragenarians. It is one of the most prevalent neurodegenerative disorders with a multifactorial pathogenesis. It ...

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of patients with Polycyt...